Dr. Voorhees on Triplet Regimen in Multiple Myeloma
Peter Voorhees, MD, associate professor, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Clinical Research, Leukemia, Lymphoma, and Myeloma Program, UNC Lineberger Comprehensive Cancer Center, discusses the triplet regimen of pomalidomide, dexamethasone, and ixazomib in patients with double refractory multiple myeloma.
Peter Voorhees, MD, associate professor, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Clinical Research, Leukemia, Lymphoma, and Myeloma Program, UNC Lineberger Comprehensive Cancer Center, discusses the triplet regimen of pomalidomide, dexamethasone, and ixazomib in patients with double refractory multiple myeloma.
A phase I study examined the triplet regimen versus pomalidomide/dexamethasone in patients who had received two prior lines of therapy, had lenalidomide-refractory disease, and were refractory to either carfilzomib or bortezomib.
The safety profile of the triplet therapy has been encouraging, Voorhees says. Grade 3/4 adverse events include neutropenia and thrombocytopenia, but are manageable. Nonhematologic toxicities are grade 1/2, he says. The overall response rate for the first 20 evaluable patients is 55%. The triplet will be investigated further with a fourth dose cohort in a randomized phase II study, Voorhees adds.
